Biophytis S.A. (0D1W.L)
| Previous Close | 0.7600 |
| Open | 0.7800 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's Range | 0.7800 - 0.8000 |
| 52 Week Range | 0.0036 - 0.8000 |
| Volume | |
| Avg. Volume | 153,519 |
| Market Cap | N/A |
| Beta (5Y Monthly) | 1.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2640 |
| Earnings Date | Apr 08, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ACCESSWIREBiophytis Announces Transfer of ADSs to OTC Market
ADSs delisted from Nasdaq, which will result in meaningful savings ADSs transferred to OTC Pink market; Company will apply to trade on OTCQB market Biophytis remains listed on Euronext Growth Paris as its primary trading market PARIS, FRANCE AND CAMBRIDGE, ...
- ACCESSWIRE
Biophytis Announces Ratio Change Under its American Depositary Receipt (“ADR”) Program
PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / April 19, 2024 / Biophytis SA (Nasdaq CM:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related ...
- ACCESSWIRE
Biophytis Announces New Scientific Advisory Board for its Phase 2 OBA Clinical Study in Obesity
IND to be filed with the FDA in the coming weeks PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 18, 2024 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized ...
